These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26955658)

  • 1. Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network.
    Kaur K; Fayad R; Saxena A; Frizzell N; Chanda A; Das S; Chatterjee S; Hegde S; Baliga MS; Ponemone V; Rorro M; Greene J; Elraheb Y; Redd AJ; Bian J; Restaino J; Norris LB; Qureshi ZP; Love BL; Brookstaver B; Georgantopoulos P; Sartor O; Raisch DW; Rao G; Lu K; Ray P; Hrusheshky W; Schulz R; Ablin R; Noxon V; Bennett CL;
    J Community Support Oncol; 2016 Feb; 14(2):54-65. PubMed ID: 26955658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.
    Bennett AC; Bennett CL; Witherspoon BJ; Knopf KB
    Expert Opin Drug Saf; 2019 Nov; 18(11):1055-1063. PubMed ID: 31500468
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system.
    Arabyat RM; Raisch DW; McKoy JM; Bennett CL
    Expert Opin Drug Saf; 2015; 14(11):1653-60. PubMed ID: 26393387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolones: old drugs, putative new toxicities.
    Bove C; Baldock RA; Champigneulle O; Martin L; Bennett CL
    Expert Opin Drug Saf; 2022 Nov; 21(11):1365-1378. PubMed ID: 36384376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).
    Wharton M; Strikas RA; Harpaz R; Rotz LD; Schwartz B; Casey CG; Pearson ML; Anderson LJ; ;
    MMWR Recomm Rep; 2003 Apr; 52(RR-7):1-16. PubMed ID: 12710832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals.
    Yarrington ME; Anderson DJ; Dodds Ashley E; Jones T; Davis A; Johnson M; Lokhnygina Y; Sexton DJ; Moehring RW
    Infect Control Hosp Epidemiol; 2019 Nov; 40(11):1297-1300. PubMed ID: 31474240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions.
    Bennett CL; Schooley B; Taylor MA; Witherspoon BJ; Godwin A; Vemula J; Ausdenmoore HC; Sartor O; Yang YT; Armitage JO; Hrushesky WJ; Restaino J; Thomsen HS; Yarnold PR; Young T; Knopf KB; Chen B
    PLoS One; 2019; 14(7):e0219521. PubMed ID: 31365527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR).
    Bennett CL; Hoque S; Olivieri N; Taylor MA; Aboulafia D; Lubaczewski C; Bennett AC; Vemula J; Schooley B; Witherspoon BJ; Godwin AC; Ray PS; Yarnold PR; Ausdenmoore HC; Fishman M; Herring G; Ventrone A; Aldaco J; Hrushesky WJ; Restaino J; Thomsen HS; Yarnold PR; Marx R; Migliorati C; Ruggiero S; Nabhan C; Carson KR; McKoy JM; Yang YT; Schoen MW; Knopf K; Martin L; Sartor O; Rosen S; Smith WK
    EClinicalMedicine; 2021 Jan; 31():100693. PubMed ID: 33554084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.
    Nevin RL; Leoutsakos JM
    Drugs R D; 2017 Mar; 17(1):199-210. PubMed ID: 28063022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New Criterion for Fluoroquinolone-Associated Disability Diagnosis: Functional Gastrointestinal Disorders.
    Cannizzaro DN; Naughton LF; Freeman MZ; Martin L; Bennett CL; Bove C
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946316
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmodal Clinical Decision Support and Antimicrobial Restriction Effects on Rates of Fluoroquinolone Use in Uncomplicated Infections.
    Gunn LR; Tunney R; Kelly K
    Appl Clin Inform; 2018 Jan; 9(1):149-155. PubMed ID: 29490408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France.
    Chalumeau M; Tonnelier S; D'Athis P; Tréluyer JM; Gendrel D; Bréart G; Pons G;
    Pediatrics; 2003 Jun; 111(6 Pt 1):e714-9. PubMed ID: 12777590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of reports of depression and suicide in patients treated with isotretinoin.
    Wysowski DK; Pitts M; Beitz J
    J Am Acad Dermatol; 2001 Oct; 45(4):515-9. PubMed ID: 11568740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of fluoroquinolone use in the respiratory intensive care unit on the development of hospital-acquired MRSA infection and its prognosis].
    Dirican N; Oz AT; Pullukçu H; Aydemir S; Bacakoğlu F
    Mikrobiyol Bul; 2014 Jan; 48(1):28-39. PubMed ID: 24506713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacists' knowledge of the safety of antibiotics for systemic use.
    Yakimova Y
    Int J Risk Saf Med; 2015; 27 Suppl 1():S11-2. PubMed ID: 26639686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
    Stobaugh DJ; Deepak P; Ehrenpreis ED
    J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.